![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Mylan, Dr. Reddy’s Release Generic Namenda
Mylan, Dr. Reddy’s Release Generic Namenda
Mylan and Dr. Reddy’s Laboratories this week each launched generic versions of Actavis’ Alzheimer’s drug Namenda.
The companies share 180-day generic drug marketing exclusivity for Namenda IR (memantine hydrochloride) as first filers of an ANDA with a paragraph IV certification. A total of 10 other generic versions may enter the market as early as October.
In May, the Second Circuit Court of Appeals upheld a lower court’s preliminary injunction requiring Actavis and partner Forest Laboratories to make its Namenda IR available until Aug. 11 nationwide.
Namenda had U.S. sales of about $1.4 billion for the 12 months ending in May, according to IMS Health. — Jonathon Shacat
Upcoming Events
-
21Oct